Argenx will purchase Forte Biosciences for $2.2 billion in cash, adding an autoimmune-focused asset to its growing immunology pipeline.
The approval of enlicitide marks an important step for cholesterol treatment, though its benefits may be limited by who can access and use it.
Federal health quality research grants tied to AHRQ have been cut short, affecting dozens of projects and leaving researchers uncertain about the future of the field.
Severe symptoms, long diagnostic delays and a lack of workplace protections are leaving some women unable to stay employed, according to accounts highlighted in a new inquiry.
A Cardiff health summit heard how women’s symptoms are still too often dismissed, as campaigners and ministers called for stronger services, better training and more say for patients.
A former London Underground cleaner who won an unfair dismissal case says the public should be aware of the asbestos and hazardous dust concerns raised by his work.
In letters responding to a STAT opinion piece, clinicians argued that primary care and specialty care are complementary, and that payment policy should better support the system patients actually need.
Advisers say the NHS should offer the MenB vaccine routinely to teenagers at around age 15, marking a shift prompted by recent outbreak concerns and new evidence.
Eli Lilly is expanding into experimental psychedelic medicines with a $2.8 billion acquisition of AtaiBeckley, a deal tied to late-stage research in treatment-resistant depression.
A lawsuit from a former Mayo Clinic employee alleges she was pushed out after objecting to questionable AI, consent, and privacy practices tied to the health system’s technology deployment.